Publications show all

Lineagen has published 16 articles.

Patents show all

43Applications5Issued

Clinical Trials show all

1N/A

SEC Filings show all

D10

Private Funding Events

DateOfferedSoldType
2015-01-26$12,173,420$12,173,420Equity, Other
2013-11-25$23,576,339$16,107,915Equity, Other
2013-04-25$25,000,000$11,594,064Equity, Debt, Option to Acquire, Security to be Acquired, Other
2013-04-05$25,000,000$11,594,064Equity, Debt, Option to Acquire, Security to be Acquired, Other
2013-04-05$25,000,000$11,594,064Equity, Debt, Option to Acquire, Security to be Acquired, Other
2013-03-01$1,000,000$150,000Debt, Option to Acquire, Security to be Acquired, Other
2012-06-01$25,000,000$3,600,000Equity, Debt, Security to be Acquired, Other
2010-06-23$5,012,787$5,012,787Equity
2010-06-22$3,500,000$1,100,000Debt
2008-10-06UnknownUnknownOther (Paper Filing)

Key Executives

  • Michael Paul
    Executive Officer, Director
  • Marc White
    Executive Officer
  • Al Harris
    Director
  • Stephen M. Prescott
    Director
  • Fred A. Middleton
    Director
  • Dinesh Patel
    Director
  • Daniel C. Wood
    Director
  • Michael M. Jerstad
    Director
  • Michael S. Paul
    Executive Officer, Director
  • Mary C. Tanner
    Director
  • Gayland K. Moffat
    Executive Officer
  • Burt De Mill
    Executive Officer
  • Lisa Dunlea
    Director
  • Gayland Moffat
    Executive Officer
  • Michael Walsh
    Director
  • Michael Fitzgerald
    Director
  • David Kabakoff
    Director